BRPI0906490A2 - Vetores de expressão de mamífero melhorados e uso dos mesmos - Google Patents

Vetores de expressão de mamífero melhorados e uso dos mesmos

Info

Publication number
BRPI0906490A2
BRPI0906490A2 BRPI0906490-7A BRPI0906490A BRPI0906490A2 BR PI0906490 A2 BRPI0906490 A2 BR PI0906490A2 BR PI0906490 A BRPI0906490 A BR PI0906490A BR PI0906490 A2 BRPI0906490 A2 BR PI0906490A2
Authority
BR
Brazil
Prior art keywords
usage
expression vectors
mammal expression
improved
improved mammal
Prior art date
Application number
BRPI0906490-7A
Other languages
English (en)
Inventor
Chung-Ming Hsieh
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BRPI0906490A2 publication Critical patent/BRPI0906490A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
BRPI0906490-7A 2008-01-15 2009-01-15 Vetores de expressão de mamífero melhorados e uso dos mesmos BRPI0906490A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2128208P 2008-01-15 2008-01-15
US10454608P 2008-10-10 2008-10-10
PCT/US2009/031136 WO2009091912A2 (en) 2008-01-15 2009-01-15 Improved mammalian expression vectors and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0906490A2 true BRPI0906490A2 (pt) 2015-07-14

Family

ID=40885886

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0906490-7A BRPI0906490A2 (pt) 2008-01-15 2009-01-15 Vetores de expressão de mamífero melhorados e uso dos mesmos

Country Status (16)

Country Link
US (3) US8187836B2 (pt)
EP (2) EP2240581B1 (pt)
JP (2) JP5635912B2 (pt)
KR (1) KR20100113112A (pt)
CN (1) CN101970655B (pt)
AU (1) AU2009206089B2 (pt)
BR (1) BRPI0906490A2 (pt)
CA (1) CA2711962A1 (pt)
ES (1) ES2579231T3 (pt)
IL (1) IL206774A0 (pt)
MX (1) MX2010007729A (pt)
NZ (2) NZ586576A (pt)
RU (1) RU2502800C2 (pt)
TW (1) TWI478937B (pt)
WO (1) WO2009091912A2 (pt)
ZA (1) ZA201004736B (pt)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
MX336813B (es) 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Anticuerpos humanos que ligan el tnfa humano.
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
CA2493067A1 (en) * 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. Treatment of tnf.alpha. related disorders
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TWI439284B (zh) 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
WO2006041970A2 (en) * 2004-10-08 2006-04-20 Abbott Biotechnology Ltd. Treatment of respiratory syncytial virus (rsv) infection
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
NZ608319A (en) 2005-05-16 2014-08-29 Abbvie Biotechnology Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
AU2006337105B2 (en) 2005-11-01 2013-05-02 Abbvie Biotechnology Ltd Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
TW201333030A (zh) 2006-04-05 2013-08-16 Abbott Biotech Ltd 抗體之純化
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
WO2007120656A2 (en) * 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
EP2007426A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
WO2007120626A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of ankylosing spondylitis
US20100021451A1 (en) 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
US20080311043A1 (en) * 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
KR101440795B1 (ko) 2006-06-30 2014-09-22 애브비 바이오테크놀로지 리미티드 자동 주사 장치
ES2442258T3 (es) 2006-10-27 2014-02-10 Abbvie Biotechnology Ltd Anticuerpos cristalinos anti-hTNF alfa
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
JP2010533181A (ja) * 2007-07-13 2010-10-21 アボツト・バイオテクノロジー・リミテツド ＴＮＦα阻害剤の肺投与のための方法及び組成物
SG183709A1 (en) 2007-08-08 2012-09-27 Abbott Lab Compositions and methods for crystallizing antibodies
NZ622583A (en) 2007-11-30 2015-08-28 Abbvie Biotechnology Ltd Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CN101965514A (zh) * 2008-01-03 2011-02-02 艾博特生物技术有限公司 预测化合物在治疗银屑病中的长期功效
EP2240581B1 (en) * 2008-01-15 2016-05-11 AbbVie Inc. Improved mammalian expression vectors and uses thereof
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
CA2760237C (en) 2009-04-29 2017-11-14 Abbott Biotechnology Ltd. Automatic injection device and plunger for same
WO2010138555A2 (en) 2009-05-26 2010-12-02 University Of Florida Research Foundation, Inc. Small peptide expression system in mammalian cells
CA2952742A1 (en) 2009-08-29 2011-03-03 Abbvie Inc. Therapeutic dll4 binding proteins
NZ600069A (en) 2009-12-15 2015-02-27 Abbvie Biotechnology Ltd Improved firing button for automatic injection device
BR112012021941A2 (pt) 2010-03-02 2022-02-01 Abbvie Inc Proteínas terapêuticas de ligação a dll4
JP2013523153A (ja) 2010-04-07 2013-06-17 アッヴィ・インコーポレイテッド ＴＮＦ−α結合タンパク質
JP5944382B2 (ja) 2010-06-03 2016-07-05 アッヴィ バイオテクノロジー リミテッド 汗腺膿瘍（ｈｓ）の治療のための使用および組成物
AU2011285852B2 (en) 2010-08-03 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
LT3333188T (lt) 2010-08-19 2022-06-10 Zoetis Belgium S.A. Anti-ngf antikūnai ir jų panaudojimas
KR20130139884A (ko) 2010-08-26 2013-12-23 애브비 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
JP6068352B2 (ja) 2010-10-29 2017-01-25 アッヴィ・インコーポレイテッド アポトーシス誘発剤を含む固体分散体
KR101841527B1 (ko) 2010-11-11 2018-03-23 애브비 바이오테크놀로지 리미티드 개선된 고농도 항－ＴＮＦα 항체 액체 제형
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose
PT2642999T (pt) 2010-11-23 2017-01-05 Abbvie Ireland Unlimited Co Métodos de tratamento que utilizam inibidores seletivos de bcl-2
US8853365B2 (en) 2010-12-21 2014-10-07 Abbvie Inc. Dual variable domain immunnoglobulins and uses thereof
EP2667918B1 (en) 2011-01-24 2017-03-01 AbbVie Biotechnology Ltd Automatic injection devices having overmolded gripping surfaces
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9249425B2 (en) * 2011-05-16 2016-02-02 The Trustees Of The University Of Pennslyvania Proviral plasmids and production of recombinant adeno-associated virus
RU2014120981A (ru) 2011-10-24 2015-12-10 Эббви Инк. Иммунные связывающие агенты против склеростина
RU2014121043A (ru) 2011-10-24 2015-12-10 Эббви Инк. Биспецифические иммуносвязывающие средства, направленные против tnf и il-17
UY34409A (es) 2011-10-24 2013-05-31 Abbvie Inc Inmunoenlazadores dirigidos contra el tnf
UY34556A (es) 2011-12-30 2013-07-31 Abbvie Inc Dominio variable dual de inmunoglobulinas y sus usos
AU2012362326A1 (en) 2011-12-30 2014-07-24 Abbvie Inc. Dual variable domain immunoglobulins against IL-13 and/or IL-17
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9670276B2 (en) 2012-07-12 2017-06-06 Abbvie Inc. IL-1 binding proteins
BR112015004467A2 (pt) 2012-09-02 2017-03-21 Abbvie Inc método para controlar a heterogeneidade de proteínas
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
AR093311A1 (es) 2012-11-01 2015-05-27 Abbvie Inc Inmunoglobulinas de dominio variable dual contra el factor de crecimiento endotelial vascular (vegf) y el ligando involucrado en la señalizacion celula a celula a traves del receptor notch (dll4)
US20140212423A1 (en) 2012-12-04 2014-07-31 Abbvie, Inc. Blood-brain barrier penetrating dual specific binding proteins
WO2014100073A2 (en) * 2012-12-21 2014-06-26 Merck Sharp & Dohme Corp. Expression vectors for recombinant protein production in mammalian cells
US9856319B2 (en) 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
WO2014106001A2 (en) 2012-12-28 2014-07-03 Abbvie, Inc. Dual specific binding proteins having a receptor sequence
CA2940513C (en) 2013-03-11 2023-08-15 University Of Florida Research Foundation, Inc. Delivery of card protein as therapy for ocular inflammation
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
AU2014240431A1 (en) 2013-03-14 2015-08-27 Abbvie Inc. Low acidic species compositions and methods for producing the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
AU2013384204B2 (en) 2013-03-14 2017-03-16 Abbvie Inc. Low acidic species compositions and methods for producing and using the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
CA2904407A1 (en) 2013-03-15 2014-09-18 Abbvie Inc. Dual specific binding proteins directed against tnf.alpha.
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
EP3052524A2 (en) 2013-10-06 2016-08-10 Abbvie Inc. Dual specific binding proteins directed against immune cell receptors and tlr signaling autoantigens
CA2926588C (en) 2013-10-16 2020-07-21 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3105311A1 (en) 2014-02-10 2016-12-21 Univercells NV System, apparatus and method for biomolecules production
EP3107939B1 (en) 2014-02-19 2020-06-17 University of Florida Research Foundation, Inc. Delivery of nrf2 as therapy for protection against reactive oxygen species
EP3116898B1 (en) * 2014-03-11 2022-01-26 University of Florida Research Foundation, Inc. Aav-expressed m013 protein as an anti-inflammatroy therapeutic for use in a method of treating inflammatory ocular disease
AR099812A1 (es) 2014-03-21 2016-08-17 Abbvie Inc Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
US20160002343A1 (en) 2014-06-11 2016-01-07 Abbvie Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
US20170226552A1 (en) 2014-07-03 2017-08-10 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
WO2016007764A1 (en) 2014-07-09 2016-01-14 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars
EP3183580A4 (en) 2014-08-21 2018-04-25 DiscoveRx Corporation Homogenous thermal shift ligand binding assay
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
US10696735B2 (en) 2015-01-21 2020-06-30 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
CN105315371B (zh) * 2015-03-05 2018-05-29 北京百特美博生物科技有限公司 抗人il-17单克隆抗体
TWI554608B (zh) * 2015-03-27 2016-10-21 Univ China Medical A nucleic acid sequence segment for enhancing protein expression, an expression vector comprising a sequence segment thereof, and a kit comprising its expression vector
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
WO2017085693A1 (en) 2015-11-19 2017-05-26 AbbVie Deutschland GmbH & Co. KG Reporter gene assay methods for identifying and analyzing multi-specific binding proteins
WO2017136433A1 (en) 2016-02-03 2017-08-10 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
AU2017301600B2 (en) 2016-07-26 2022-08-04 Biomarin Pharmaceutical Inc. Novel adeno-associated virus capsid proteins
BR112019009834B1 (pt) 2016-11-17 2022-05-17 Ohio State Innovation Foundation Vetor viral adeno-associado recombinante (raav), vírus, composição farmacêutica e uso de um vetor raav
EA201992001A1 (ru) 2017-03-17 2020-01-24 Адверум Байотекнолоджис, Инк. Композиции и способы повышения экспрессии генов
CN110352201A (zh) 2017-04-03 2019-10-18 免疫医疗公司 用于癌症疗法的抗体药物缀合物的皮下施用
EP3621630A4 (en) 2017-06-14 2021-03-10 The Children's Medical Center HEMATOPOIETIC STEM AND PRECURSOR CELLS FROM HEMOGENIC ENDOTHELIAL CELLS BY EPISOMAL PLASMID GENERAL TRANSFER
CN107254481A (zh) * 2017-06-15 2017-10-17 江苏迈健生物科技发展股份有限公司 人重组表皮生长因子MJ‑hEGF基因优化序列及其制备方法和应用
CN107254472A (zh) * 2017-06-15 2017-10-17 江苏迈健生物科技发展股份有限公司 人表皮生长因子hEGF基因优化序列及其制备方法和应用
DK3737397T3 (da) 2017-12-13 2023-02-20 Inovio Pharmaceuticals Inc Cancervacciner mod PRAME og anvendelse deraf
JP7485600B2 (ja) 2017-12-13 2024-05-16 イノビオ ファーマシューティカルズ，インコーポレイティド Ｂｏｒｉｓを標的とするがんワクチンおよびその使用
JP2021522811A (ja) 2018-05-09 2021-09-02 ビオマリン プハルマセウトイカル インコーポレイテッド フェニルケトン尿症の治療方法
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2023244746A1 (en) 2022-06-15 2023-12-21 Abbvie Inc. Risankizumab compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3431140A1 (de) 1984-08-24 1986-03-06 Behringwerke Ag, 3550 Marburg Enhancer fuer eukaryotische expressionssysteme
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
DK0897983T3 (da) 1991-10-25 2003-08-11 Immunex Corp Antistoffer mod CD40-L
WO1996040918A2 (en) 1995-06-07 1996-12-19 Immunex Corporation Novel cd40l mutein
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
AU3663699A (en) * 1998-04-24 1999-11-16 University Of Florida Materials and methods for gene therapy
US6440741B2 (en) * 1999-03-15 2002-08-27 The Trustees Of Columbia University In The City Of New York Expression vector for consistent cellular expression of the tet on repressor in multiple cell types
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
EP1644508A1 (en) * 2003-07-11 2006-04-12 Cytos Biotechnology AG Gene expression system
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US20060018902A1 (en) 2004-04-09 2006-01-26 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
EA010350B1 (ru) * 2004-06-03 2008-08-29 Новиммун С.А. Антитела против cd3 и способы их применения
RU2478709C2 (ru) * 2005-07-21 2013-04-10 Эбботт Лэборетриз ЭКСПРЕССИЯ МНОЖЕСТВА ГЕНОВ, ВКЛЮЧАЯ sORF-КОНСТРУКЦИИ, И СПОСОБЫ ЭКСПРЕССИРОВАНИЯ ИММУНОГЛОБУЛИНА
EP2240581B1 (en) * 2008-01-15 2016-05-11 AbbVie Inc. Improved mammalian expression vectors and uses thereof

Also Published As

Publication number Publication date
TWI478937B (zh) 2015-04-01
AU2009206089A1 (en) 2009-07-23
ES2579231T3 (es) 2016-08-08
CN101970655A (zh) 2011-02-09
CN101970655B (zh) 2014-03-05
US20090239259A1 (en) 2009-09-24
JP2014147390A (ja) 2014-08-21
NZ600979A (en) 2014-01-31
EP2240581A4 (en) 2011-06-22
WO2009091912A3 (en) 2009-09-24
EP2240581B1 (en) 2016-05-11
RU2010133938A (ru) 2012-02-27
NZ586576A (en) 2012-08-31
WO2009091912A2 (en) 2009-07-23
US20130344537A1 (en) 2013-12-26
IL206774A0 (en) 2010-12-30
CA2711962A1 (en) 2009-07-23
TW200940563A (en) 2009-10-01
KR20100113112A (ko) 2010-10-20
AU2009206089B2 (en) 2014-08-28
RU2502800C2 (ru) 2013-12-27
MX2010007729A (es) 2010-08-04
US8187836B2 (en) 2012-05-29
ZA201004736B (en) 2012-05-30
JP2011509673A (ja) 2011-03-31
JP5635912B2 (ja) 2014-12-03
EP2784089A1 (en) 2014-10-01
US8455219B2 (en) 2013-06-04
EP2240581A2 (en) 2010-10-20
US20120237976A1 (en) 2012-09-20

Similar Documents

Publication Publication Date Title
BRPI0906490A2 (pt) Vetores de expressão de mamífero melhorados e uso dos mesmos
BRPI1012533A2 (pt) composto de piradazinona e uso do mesmo
AT506816B1 (de) Vlf-prüfgenerator
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
CR20130360A (es) Compuesto heterocíclico y su uso
BRPI1015315A2 (pt) composto heterocíclico fundido e uso dos mesmos
BRPI1004349A2 (pt) conjunto de rótulo e uso do mesmo
DOP2010000260A (es) Derivado heterociclico fusionado y su uso
BRPI0922708A2 (pt) peptídeos mini-hepcidina e métodos de uso do mesmo
DK2349430T3 (da) KATETERISERINGANORDNING og -kit
BRPI1010024A2 (pt) derivados de aminopirrolidinona e uso dos mesmos
BRPI0906478A2 (pt) anticorpo anti-nr10 e uso do mesmo
DK2201858T3 (da) Hårtørrer
BR112012001260A2 (pt) conjugados de epsilon-polilisina e o emprego dos mesmos
BRPI1007494A2 (pt) composto e uso do mesmo
BR112012004731A2 (pt) peptídeos derivados de wnt10 e uso dos mesmos
BRPI1014544A2 (pt) anticorpors anti-il-17f e metodos de uso dos mesmos
SMT201500218B (it) Composti aril-fenil-solfonammido-cicloalchile e loro uso
DK2325662T3 (da) Multi-indlæsnings- og multi-udlæsningsanalysator
BRPI0921044A2 (pt) composto heterocíclico de acenafto, composto de inclusão de ciclodextrina do composto heterocíclico de acenafto, complexo de ciclodextrina do composto heterocíclico de acenafto, uso do composto heterocíclico de acenafto, uso do composto de inclusão de ciclodextrina do composto heterocíclico de acenafto e uso do complexo de ciclodextrina
BRPI0909840A2 (pt) Uso de 4-tio-2-deoxinucleosídios
BRPI0917914A2 (pt) estrutura de guindaste
BRPI0915405A2 (pt) 7-sulfanilmetil-, 7-sulfinilmetil- e 7-sulfonilmetil-indóis substituídos e uso dos mesmos
IT1391735B1 (it) Dispositivo di essiccazione
SMT201600217B (it) Furancarbossamidi sostituite e loro uso

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ABBVIE INC. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]